Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 16/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 11/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 11/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 11/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 11/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 11/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 11/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19457708 | 0.87 | USP30 (0.45) | KCNJ1KCNH2USP30 | |
| SCHEMBL20872894 | 0.85 | KCNJ1 (0.53) | KCNJ1KCNH2PRKAA2PRKAB2PRKAG1 | |
| SCHEMBL19473772 | 0.85 | KCNJ1 (0.41) | KCNJ1KCNH2PRKAA2 | |
| Trifluoroacetic Acid SCHEMBL19639843 | 0.82 | SCN9A (0.40) | KCNJ1KCNH2PRKAA2 | |
| Trifluoroacetic Acid SCHEMBL19457706 | 0.81 | L3MBTL1 (0.42) | KCNJ1USP30 | |
| SCHEMBL19457848 | 0.76 | KCNJ1 (0.53) | KCNJ1KCNH2USP30 | |
| SCHEMBL19473749 | 0.74 | KCNJ1 (0.65) | KCNJ1KCNH2 | |
| SCHEMBL19473769 | 0.73 | NSD2 (0.52) | KCNJ1KCNH2USP30 | |
| SCHEMBL19457712 | 0.73 | KCNJ1 (0.87) | KCNJ1KCNH2 | |
| SCHEMBL19457869 | 0.73 | KCNJ1 (0.87) | KCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759788-B2 | Pharmaceutical uses of pyridine carboxamide derivatives | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| US-10442794-B2 | Processes for preparing pyridine carboxamide derivatives | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-10-15 | — | — | US | disclosed |
| US-10364234-B2 | Pyridinecarboxamide derivatives, preparation method thereof and pharmaceutical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-07-30 | — | — | US | disclosed |
| US-20190152958-A1 | PHARMACEUTICAL USES OF PYRIDINE CARBOXAMIDE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20190152959-A1 | PROCESSES FOR PREPARING PYRIDINE CARBOXAMIDE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152958-A1 | PHARMACEUTICAL USES OF PYRIDINE CARBOXAMIDE DERIVATIVES | CASK, PDXK, NADK | KCNJ1 9/4885KCNH2 38/4885PRKAA2 312/4885 |
| US-20190152959-A1 | PROCESSES FOR PREPARING PYRIDINE CARBOXAMIDE DERIVATIVES | CPS1, PDXK, SDHA | KCNJ1 2381/4885KCNH2 1134/4885PRKAA2 1687/4885 |
| US-10442794-B2 | Processes for preparing pyridine carboxamide derivatives | CPS1, PDXK, SDHA | KCNJ1 2381/4885KCNH2 1134/4885PRKAA2 1687/4885 |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | KCNK2, KCNJ2, KCNK5 | KCNJ1 7/4885KCNH2 15/4885PRKAA2 701/4885 |
| US-10364234-B2 | Pyridinecarboxamide derivatives, preparation method thereof and pharmaceutical uses thereof | KCNK2, KCNJ2, KCNK5 | KCNJ1 7/4885KCNH2 15/4885PRKAA2 701/4885 |
| US-10759788-B2 | Pharmaceutical uses of pyridine carboxamide derivatives | CASK, PDXK, NADK | KCNJ1 9/4885KCNH2 38/4885PRKAA2 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.